The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
Open accessPublished version of a preprint
Abstract
Chimeric antigen receptor (CAR)–modified T cells with anti-CD19 specificity are a highly effective novel immune therapy for relapsed/refractory acute lymphoblastic leukemia. Cytokine release syndrome (CRS) is the most significant and life-threatening toxicity. To improve understanding of CRS, we measured cytokines and clinical biomarkers in 51 CTL019-treated patients. Peak levels of 24 cytokines, including IFNγ, IL6, sgp130, and sIL6R, in the first month after infusion were highly associated with severe CRS. Using regression modeling, we could accurately predict which patients would develop severe CRS with a signature composed of three cytokines. Results were validated in an independent cohort. Changes in serum biochemical markers, including C-reactive protein and ferritin, were associated with CRS but failed to predict development of severe CRS. These comprehensive profiling data provide novel insights into CRS biology and, importantly, represent the first data that can accurately predict which patients have a high probability of becoming critically ill. Significance: CRS is the most common severe toxicity seen after CAR T-cell treatment. We developed models that can accurately predict which patients are likely to develop severe CRS before they become critically ill, which improves understanding of CRS biology and may guide future cytokine-directed therapy. Cancer Discov; 6(6); 664–79. ©2016 AACR. See related commentary by Rouce and Heslop, p. 579. This article is highlighted in the In This Issue feature, p. 561
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most severe of these immune-related adverse events (irAEs) are cytokine release syndrome (CRS) and neurotoxicity, most prominently described in patients treated with CAR-T-cells [6–11].”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [7]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Immune checkpoint blockade induces irAEs during short-term follow-up of some patients with cancer, though robust immune biomarkers correlating with adverse effects of therapy are still being investigated [1, 4, 7, 20–25].”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [7]
Experimental — accuracy not yet measuredIn the citing paper
“Serum biomarkers, including glycoprotein 130 (gp130), interferon-γ, and interleukin-1–receptor antagonist (IL1RA), can be used to predict the severity of cytokine storm induced by CAR T-cell therapy”
From Cytokine storm (2020) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Self-citationChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Self-citationChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Self-citationLee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Self-citationEfficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Self-citationRose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040 · cited 3×
“In other IL6-mediated diseases, IL6 levels often go up and sIL6R levels either increase or decrease after treatment as the interaction between IL6R and IL6 is blocked (21, 23, 24).”
BackgroundSelf-citationBorowitz, M. J., Devidas, M., Hunger, S. P., Bowman, W. P., Carroll, A. J., Carroll, W. L., Linda, S. B., Martin, P. L., Pullen, D. J., Viswanatha, D. S., et al. (2008) · Blood · doi:10.1182/blood-2008-01-132837 · Cited by 841
Cited by
Sorted by citations
Items 501–600 of 1,000
Hua, J., Zhang, J., Wu, X., Zhou, L., Bao, X., Han, Y., Miao, M., Li, C., Fu, Z., Wu, D., et al. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.04.007 · Cited by 22
Oncologic Emergencies: Immune-Based Cancer Therapies and Complications
Long, B., Brem, E. A., & Koyfman, A. (2020) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2020.1.45898 · Cited by 22
Coronavirus Disease-2019 Treatment Strategies Targeting Interleukin-6 Signaling and Herbal Medicine
Dzobo, K., Chiririwa, H., Dandara, C., & Dzobo, W. (2020) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2020.0122 · Cited by 22
Need for standardization of cytokine profiling in CAR T cell therapy
Biery, D. N., Turicek, D. P., Diorio, C. J., Schroeder, B., & Shah, N. N. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.030 · Cited by 21
Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?
Stahl, M. F., Lu, B. Y., Kim, T. K., & Zeidan, A. M. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0503-8 · Cited by 22
The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma.
Lulla, P., Hill, L. C., Ramos, C. A., & Heslop, H. E. (2018) · PubMed · Cited by 21
Advances in CAR T Therapy for Hematologic Malignancies
Freyer, C. W., & Porter, D. L. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2414 · Cited by 21
Self-citationThe Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies
Zhylko, A., Winiarska, M., & Graczyk‐Jarzynka, A. (2020) · Cancers · doi:10.3390/cancers12082030 · Cited by 21
Biomarkers for predicting the outcome of various cancer immunotherapies
Jafarzadeh, L., Khakpoor-Koosheh, M., Mirzaei, H., & Mirzaei, H. R. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103161 · Cited by 21
Asghar, M. S., Yasmin, F., Ahsan, M. N., Alvi, H., Taweesedt, P., & Surani, S. (2021) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2021.1949793 · Cited by 21
Mansouri, V., Yazdanpanah, N., & Rezaei, N. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.1984449 · Cited by 21
He, P., Liu, H., Zimdahl, B., Wang, J., Luo, M., Chang, Q., Tian, F., Fan, N., Yu, D., Liu, H., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04132-9 · Cited by 22
Self-citationGong, W., Qiu, Y., Li, M., Chen, L., Li, Y., Yu, J.-Q., Kang, L., Sun, A., Wu, D., Yu, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.922212 · Cited by 22
Neurological adverse effects of chimeric antigen receptor T-cell therapy
Saleki, K., Mohamadi, M. H., Alijanizadeh, P., & Rezaei, N. (2023) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2248390 · Cited by 23
Mochel, J. P., Ekker, S. C., Johannes, C. M., Jergens, A. E., Allenspach, K., Bourgois‐Mochel, A., Knouse, M., Benzekry, S., Wierson, W. A., LeBlanc, A. K., et al. (2019) · The AAPS Journal · doi:10.1208/s12248-019-0322-1 · Cited by 23
Donnenberg, A. D., Luketich, J. D., & Donnenberg, V. S. (2019) · Oncotarget · doi:10.18632/oncotarget.27290 · Cited by 21
Uppuluri, R., Swaminathan, V. V., Ramanan, K. M., Meena, S. K., Varla, H., Ramakrishnan, B., Jayakumar, I., & Raj, R. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.08.019 · Cited by 21
Gerard, E., Zohar, S., Thai, H., Lorenzato, C., Riviere, M., & Ursino, M. (2021) · Biometrics · doi:10.1111/biom.13433 · Cited by 21
Sytsma, B. J., Allain, V., Bourke, S., Faizee, F., Fathi, M., Ferreira, L. M. R., Brewer, W. J., Li, L., Pan, F. L., Rothrock, A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-89070-5 · Cited by 20
Wang, X. W., He, X., Zhang, T., Liu, J., & Zhao, M. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06467-y · Cited by 22
Chimeric Antigen Receptor T-Cell Therapy: Reach to Solid Tumor Experience
Metzinger, M. N., Verghese, C., Hamouda, D., Lenhard, A., Choucair, K., Senzer, N. N., Brunicardi, F. C., Dworkin, L. D., & Nemunaitis, J. J. (2019) · Oncology · doi:10.1159/000500488 · Cited by 20
Qian, S., Villarejo‐Campos, P., Castellano, I. G., Hernández‐Villafranca, S., García‐Olmo, D., González-Soares, S., Guadalajara, H., Jiménez-Galanes, S., & Qian, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.841425 · Cited by 20
Human induced-T-to-natural killer cells have potent anti-tumour activities
Jiang, Z., Qin, L., Tang, Y., Liao, R. J., Shi, J., He, B., Li, S., Zheng, D., Cui, Y., Wu, Q., et al. (2022) · Biomarker Research · doi:10.1186/s40364-022-00358-4 · Cited by 20
Nano-Biohybrid DNA Engager That Reprograms the T-Cell Receptor
Ma, P., Liu, T.-X., Li, H., Yin, B., & Ye, B. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c05903 · Cited by 20
Kheyrolahzadeh, K., Tohidkia, M. R., Tarighatnia, A., Shahabi, P., Nader, N. D., & Aghanejad, A. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121917 · Cited by 20
Khanam, R., Faiman, B. M., Batool, S., Najmuddin, M. M., Usman, R. M., Kuriakose, K., Ahmed, A., Rehman, M. E. U., Roksana, Z., Syed, Z., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175539 · Cited by 20
Perl, M., Herfeld, K., Harrer, D. C., Höpting, M., Schweiger, M., Sterz, U., Knödler, L., Heimerl, S., Hansmann, L., Herr, W., et al. (2024) · Haematologica · doi:10.3324/haematol.2023.284564 · Cited by 20
Cytokine Release Syndrome after Haploidentical Stem Cell Transplantation
Teachey, D. T., & Grupp, S. A. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.08.010 · Cited by 20
Self-citationChimaeric antigen receptor T-cell therapy for tumour immunotherapy
Sha, H., Wang, D., Yan, D., Hu, Y., Yang, S., Liu, S.-W., & Feng, J. (2017) · Bioscience Reports · doi:10.1042/bsr20160332 · Cited by 21
Mariotti, J., Taurino, D., Marino, F., Bramanti, S., Sarina, B., Morabito, L., Philippis, C. D., Vito, C. D., Mavilio, D., Carlo‐Stella, C., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2607 · Cited by 21
The promise of chimeric antigen receptor T cells ( CART s) in leukaemia
Orlowski, R. J., Porter, D. L., & Frey, N. V. (2016) · British Journal of Haematology · doi:10.1111/bjh.14475 · Cited by 21
Self-citationFrigault, M. J., Yao, N., Berger, T. R., Wehrli, M., Gallagher, K., Horick, N., Graham, C., Jacobson, C. A., Chen, Y., Leick, M. B., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015161 · Cited by 21
Genome editing of immune cells using CRISPR/Cas9
Kim, S., Hupperetz, C., Kim, C. H., & Kim, C. H. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.1.245 · Cited by 21
Sun, Z., Xun, R., Liu, M., Wu, X., & Qu, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.646450 · Cited by 19
Li, P., Liu, Y., Liang, Y., Bo, J., Gao, S., Hu, Y., Hu, Y., Huang, H., Huang, X., Jing, H., et al. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2022.0585 · Cited by 19
Liu, R., Lv, Y., Hong, F., Zhao, W., Lei, B., Liu, J., Zhang, W., He, A., & Wang, F. (2023) · Hematological Oncology · doi:10.1002/hon.3155 · Cited by 19
Wang, H., Tang, L. Y., Kong, Y., Liu, W., Zhu, X., & You, Y. H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119115 · Cited by 19
Hammill, J. A., Kwiecień, J. M., Dvorkin‐Gheva, A., Lau, V. W. C., Baker, C. L., Wu, Y., Bezverbnaya, K., Aarts, C. W., Heslen, C. W., Denisova, G. F., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.04.001 · Cited by 19
Naidoo, J., Reuss, J. E., Suresh, K. S., Feller-Kopman, D. J., Forde, P. M., Steinke, S. M., Rock, C., Johnson, D. B., Nishino, M., & Brahmer, J. R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000984 · Cited by 19
Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia
Barsan, V. V., Ramakrishna, S., & Davis, K. L. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0875-2 · Cited by 19
Future directions in chimeric antigen receptor T cell therapy
Maude, S. L. (2017) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000436 · Cited by 18
Self-citationFröse, J., Rowley, J. E., Farid, A. S., Rakhshandehroo, T., Leclerc, P., Mak, H. H., Allen, H. H., Moravej, S. H., Munaretto, L., Millán-Barea, L. R., et al. (2024) · Science Advances · doi:10.1126/sciadv.adn3816 · Cited by 18
Schultz, L. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01985 · Cited by 18
CAR T-cell therapy in mature lymphoid malignancies: clinical opportunities and challenges
Narkhede, M. S., Mehta, A., Ansell, S. M., & Goyal, G. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-5546 · Cited by 19
Pemmaraju, N., Wilson, N. R., Senapati, J., Economides, M. P., Guzmán, M. L., Neelapu, S. S., Kazemimood, R., Davis, R. E., Jain, N., Khoury, J. D., et al. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.106928 · Cited by 18
Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors
Chen, X., Li, P., Tian, B., & Kang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1079181 · Cited by 19
Morbelli, S. D., Gambella, M., Raiola, A. M., Ghiggi, C., Bauckneht, M., Raimondo, T. D., Lapucci, C., Sambuceti, G., Inglese, M., & Angelucci, E. (2023) · Journal of Neuroimaging · doi:10.1111/jon.13135 · Cited by 18
Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy
Mulgaonkar, A., Udayakumar, D., Yang, Y., Harris, S. F., Öz, O. K., Geethakumari, P. R., & Sun, X. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1199146 · Cited by 18
Zhai, W., Wang, Z., Ye, C., Ke, L., Wang, H., & Liu, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417215 · Cited by 18
Magalhaes, I., Kalland, I., Kochenderfer, J. N., Österborg, A., Uhlin, M., & Mattsson, J. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000193 · Cited by 18
Chávez, J. C., Jain, M. D., & Kharfan‐Dabaja, M. A. (2019) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2019.05.005 · Cited by 18
Godbersen, C., Coupet, T. A., Grada, Z., Zhang, S. C., & Sentman, C. L. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1901401 · Cited by 20
Toxicities associated with adoptive cellular therapies
Hansen, D. K., Dam, M., & Faramand, R. G. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101287 · Cited by 18
Toxicities associated with immunotherapies for hematologic malignancies
Leick, M. B., & Maus, M. V. (2018) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2018.03.004 · Cited by 18
The future of cellular immunotherapy for childhood leukemia
Bonifant, C. L., & Tasian, S. K. (2019) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000866 · Cited by 19
Ronsley, R. J., Bertrand, K. C., Song, E. Z., Timpanaro, A., Choe, M., Tlais, D., Vitanza, N. A., & Park, J. R. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10208-4 · Cited by 17
The role of cytokines in cytokine release syndrome (CRS) after CAR T cell therapy
Gabriel, K., Heinzerling, L., von Baumgarten, L., Subklewe, M. S., & Kobold, S. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2026.120115 · Cited by 17
Solh, M., Dickhaus, E. A., Solomon, S. R., Morris, L. E., Zhang, X., Holland, H. K., & Bashey, A. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0522-4 · Cited by 17
Imaging and therapeutic targeting of the tumor immune microenvironment with biologics
Arnouk, S. M., Groof, T. W. M. D., & Ginderachter, J. A. V. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114239 · Cited by 17
Dalal, P., Patel, N. P., Feinstein, M. J., & Akhter, N. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221132927 · Cited by 17
Evaluation of the Tocilizumab therapy in human cancers: Latest evidence and clinical potential
Ghasemi, K., & Ghasemi, K. (2022) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13781 · Cited by 17
Matteis, S. D., Dicataldo, M., Casadei, B., Storci, G., Laprovitera, N., Arpinati, M., Maffini, E., Cortelli, P., Guarino, M., Vaglio, F., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1058126 · Cited by 17
Mu, X., Chen, C., Dong, L., Kang, Z., Sun, Z., Chen, X., Zheng, J., & Zhang, Y. (2023) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2023101 · Cited by 18
Sakunrangsit, N., Khuisangeam, N., Inthanachai, T., Yodsurang, V., Taechawattananant, P., Suppipat, K., & Tawinwung, S. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03685-7 · Cited by 17
Bianchi, M., Reichen, C., Croset, A., Fischer, S., Eggenschwiler, A., Grübler, Y., Marpakwar, R., Looser, T., Spitzli, P., Herzog, C., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0692 · Cited by 17
Reprint of: Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR
Perales, M., Kebriaei, P., Kean, L. S., & Sadelain, M. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.12.789 · Cited by 17
Predicting Dangerous Rides in CAR T Cells: Bridging the Gap between Mice and Humans
Ruella, M., & June, C. H. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.005 · Cited by 17
Self-citationCutmore, L. C., Brown, N. F., Raj, D., Chauduri, S., Wang, P., Maher, J. F., Wang, Y., Lemoine, N. R., & Marshall, J. F. (2020) · Pancreatology · doi:10.1016/j.pan.2020.02.006 · Cited by 18
CAR T cells vs allogeneic HSCT for poor-risk ALL
Diorio, C. J., & Maude, S. L. (2020) · Hematology · doi:10.1182/hematology.2020000172 · Cited by 17
Self-citationZhang, H., Liu, M., Li, Q., Lyu, C., Jiang, Y., Meng, J., Li, J., & Deng, Q. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1986216 · Cited by 17
Cell-based immunotherapy in gynecologic malignancies
Schaar, B. T., Krishnan, V., Tallapragada, S., & Dorigo, O. (2017) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000433 · Cited by 17
Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia
Ceppi, F., & Gardner, R. A. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000375 · Cited by 17
Harnessing immunotherapy for pediatric T-cell malignancies
Diorio, C. J., & Teachey, D. T. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1732819 · Cited by 17
Self-citationEngineering self-propelled tumor-infiltrating CAR T cells using synthetic velocity receptorsPreprint
Johnston, A. C., Alicea, G. M., Lee, C., Patel, P. V., Hanna, E. A., Vaz, E., Forjaz, A., Wan, Z., Nair, P. R., Lim, Y., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.13.571595 · Cited by 18
Panoskaltsis, N., McCarthy, N. E., Stagg, A. J., Mummery, C. J., Husni, M., Arebi, N., Greenstein, D., Price, C. L., Al-Hassi, H. O., Koutinas, M., et al. (2021) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02725-2 · Cited by 16
Sharma, A., Campbell, M. T., Yee, C., Goswami, S., & Sharma, P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-7020-6896-6.00077-6 · Cited by 17
Krzych, Ł. J., Putowski, Z., Czok, M., & Hofman, M. (2021) · Viruses · doi:10.3390/v13081484 · Cited by 16
Sun, Z., & Liu, M. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.03.009 · Cited by 16
Joshi, A., Ramanujan, S., & Jin, J. Y. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106380 · Cited by 16
Song, H. W., Benzaoui, M., Dwivedi, A., Underwood, S., Shao, L., Achar, S. R., Posarac, V., Remley, V. A., Procházková, M., Cai, Y., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101171 · Cited by 17
Cytokine storm and translating IL-6 biology into effective treatments for COVID-19
Li, T., Wang, D., Wei, H., & Xu, X. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-1044-4 · Cited by 16
Early induction of cytokine release syndrome by rapidly generated CAR T cells in preclinical models
Jamali, A., Ho, N., Braun, A., Adabi, E., Thalheimer, F. B., & Buchholz, C. J. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00055-9 · Cited by 17
CAR-T cell and Personalized Medicine
Cruz‐Ramos, M., & García‐Foncillas, J. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-24100-1_9 · Cited by 17
Pharmacologic Control of CAR T Cells
Caulier, B., Enserink, J. M., & Wälchli, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094320 · Cited by 17
Engineering a natural ligand-based CAR: directed evolution of the stress-receptor NKp30
Butler, S. E., Brog, R. A., Chang, C. H., Sentman, C. L., Huang, Y. H., & Ackerman, M. E. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02971-y · Cited by 16
Dong, R., Jiang, S., Chen, Y., Ma, Y., Sun, L., Xing, C., Zhang, S., & Yu, K. (2021) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2021.0057 · Cited by 16
Atherton, M. J., Rotolo, A., Haran, K. P., & Mason, N. J. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.824982 · Cited by 16
Investigation of CRS-associated cytokines in CAR-T therapy with meta-GNN and pathway crosstalk
Wei, Z., Cheng, Q., Xu, N., Zhao, C., Xu, J., Kang, L., Lou, X., Yu, L., & Feng, W. (2022) · BMC Bioinformatics · doi:10.1186/s12859-022-04917-2 · Cited by 16
Myers, R. M., Dolan, J. G., & Teachey, D. T. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1828067 · Cited by 17
Self-citationBiomarkers in Chimeric Antigen Receptor T-cell Therapy
Kong, W., Lacey, S. F., Melenhorst, J. J., & Fraietta, J. A. (2018) · Biomarkers in Medicine · doi:10.2217/bmm-2018-0054 · Cited by 16
Self-citationIntermetallic nanoassemblies potentiate systemic STING activation
Zhou, X., Ling, X., Sun, X., Wan, Z., Dwyer, T., Moore, T. C., Li, Q., Dobson, H. E., Wu, Q., Kong, X., et al. (2026) · Science · doi:10.1126/science.adx1893 · Cited by 16
Bai, Z., Su, G., & Fan, R. (2021) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2021.02.004 · Cited by 17
Facing CAR T Cell Challenges on the Deadliest Paediatric Brain Tumours
Ferreras, C., Fernández, L., Villa, L. C., Ibáñez-Navarro, M., Martín-Cortázar, C., Esteban‐Rodríguez, I., Saceda-Gutierrez, J. M., & Pérez‐Martínez, A. (2021) · Cells · doi:10.3390/cells10112940 · Cited by 15
Yoo, J. W. (2023) · Blood Research · doi:10.5045/br.2023.2023026 · Cited by 19
Caballero, M., Alonso‐Saladrigues, A., Bobillo‐Pérez, S., Faura, A., Arqués, L., Rivera, C., Català, A., Dapena, J. L., Rives, S., & Jordán, I. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1219289 · Cited by 15
Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies
Zu, Y., Ren, Q., Zhang, J., Su, H., Lu, Q., Song, Y., & Zhou, J. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00577-5 · Cited by 15
CAR T-Cell Therapy: Pediatric Patients With Relapsed and Refractory Acute Lymphoblastic Leukemia
Callahan, C. A., Baniewicz, D., & Ely, B. (2017) · Clinical journal of oncology nursing · doi:10.1188/17.cjon.s2.22-28 · Cited by 15
Self-citationSharpe, M. E. (2018) · Toxicologic Pathology · doi:10.1177/0192623317752101 · Cited by 15
Tanaka, K., Kato, I., Tanaka, M., Morita, D., Matsuda, K., Takahashi, Y., Nakahata, T., Umeda, K., Hiramatsu, H., Adachi, S., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.05.013 · Cited by 15
Rallis, K. S., Hillyar, C., Sideris, M. C., & DAVIES, J. K. (2021) · Anticancer Research · doi:10.21873/anticanres.14870 · Cited by 16
Metadata
- Authors
- Teachey, D. T., Lacey, S. F., Shaw, P. A., Melenhorst, J. J., Maude, S. L., Frey, N., Pequignot, E., Gonzalez, V. E., Chen, F., Finklestein, J., Barrett, D. M., Weiss, S. L., Fitzgerald, J. C., Berg, R. A., Aplenc, R., Callahan, C., Rheingold, S. R., Zheng, Z., Rose-John, S., White, J. C., Nazimuddin, F., Wertheim, G., Levine, B. L., June, C. H., Porter, D. L., & Grupp, S. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- University of Pennsylvania (US)
- 10Institute of Biochemistry, CAU Kiel, Germany.
- Alexander T. Augusta Military Medical Center (US)
- Corresponding author
- Teachey, David T.
- ORCID
- Teachey, David T.
- Lacey, Simon F.
- Shaw, Pamela A.
- Melenhorst, J. Joseph
- Maude, Shannon L.
- Frey, Noelle
- Gonzalez, Vanessa E.
- Chen, Fang
- Barrett, David M.
- Weiss, Scott L.
- Fitzgerald, Julie C.
- Berg, Robert A.
- Aplenc, Richard
- Callahan, Colleen
- Rheingold, Susan R.
- Zheng, Zhaohui
- Wertheim, Gerald
- Levine, Bruce L.
- June, Carl H.
- Porter, David L.
- Grupp, Stephan A.
- Venue
- Cancer Discovery
- Published
- 2016-06-01
- Volume
- 6
- Issue
- 6
- Pages
- 664-679
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC5448406
- OpenAlex
- W2340435799
- Cited by
- 1,102
- References
- 35
- Citations by year
- 2026: 72 · 2025: 116 · 2024: 94 · 2023: 110 · 2022: 102 · 2021: 142 · 2020: 181 · 2019: 103 · 2018: 93 · 2017: 64 · 2016: 22
- FWCI
- 50.70
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA165206, R01CA102646, R01CA116660, R01CA193776, P30CA016520)
- National Institute of General Medical Sciences (K23GM110496)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- cytokine release syndrome, CAR T-cell therapy, acute lymphoblastic leukemia, CD19 CAR T cells, tisagenlecleucel, predictive biomarkers, cytokine profiling, interferon-gamma, interleukin-6, soluble gp130, C-reactive protein, ferritin, relapsed/refractory leukemia, toxicity prediction
- MeSH terms
- Adolescent, Adult, Aged, Child, Child, Preschool, Female, Humans, Immunotherapy, Male, Middle Aged, Phenotype, Prognosis, Receptors, Antigen, T-Cell, ROC Curve, Severity of Illness Index, Tumor Lysis Syndrome, Biomarkers, Cytokines, Treatment Outcome, Antigens, CD19, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult, Antibodies, Monoclonal, Humanized, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
